Paul Fehlner is Chief Intellectual Property Officer for
Axcella Health, a Cambridge, Massachusetts biopharmaceutical startup. He is
also a Principal of Life Sciences Innovation LLC, a consulting company he
founded in 2017 to advise on complex IP business strategy for products and
technologies in life sciences, develop capabilities of legal and IP
professionals, and provide BD&L support for research institutes, companies,
and investors.
Previously, Dr. Fehlner was Head of Intellectual Property
for Novartis Pharma in Basel, Switzerland. In this role, he led a team
responsible for obtaining, maintaining, and enforcing IP rights. The team
created a holistic IP portfolio around Pharma’s products, including patents,
trademarks, regulatory exclusivities, and reputation. They worked closely with
global R&D and commercial organizaitons, local country organizations, and
third-party stakeholders to ensure Novartis had a foundation to bring
lifesaving and life-changing medicines to patients.
Dr. Fehlner joined Novartis in 2008 from Baker Botts, where
he was a partner specializing in IP counselling and strategic planning in the
pharmaceutical, biotechnology and medical device industries, as well as
litigation. His career includes seven years as an associate and partner at
Darby & Darby, with earlier experience as Biotechnology Counsel for
Rhône-Poulenc Rorer and as an associate for boutique IP firm Klauber &
Jackson. Dr. Fehlner started his career in life sciences law in 1990 as a law clerk
in the biotech and pharmaceutical group at Pennie & Edmonds. In addition to
life sciences, Dr. Fehlner has worked on chemical and material sciences
technologies.
Dr. Fehlner has a JD from Fordham University School of Law,
a PhD in immunology and biochemistry from Rockefeller University (Lois P Markey
Fellow), and a BS in chemistry from Haverford College (high honors; Phi Beta
Kappa).
Check out the incredible speaker line-up to see who will be joining Paul.
Download The Latest Agenda